Pharma Stocks
-
Investors Don’t See Light At End Of Aurobindo Pharma Limited’s (NSE:AUROPHARMA) Tunnel
With a price-to-earnings (or “P/E”) ratio of 20.8x Aurobindo Pharma Limited (NSE:AUROPHARMA) may be sending bullish signals at the moment,…
Read More » -
EyePoint Pharmaceuticals (EYPT) Is Up 8.4% After Positive Phase 3 Safety Review for DURAVYU
EyePoint Pharmaceuticals recently announced that the independent Data Safety Monitoring Committee completed its second scheduled review of the pivotal Phase…
Read More » -
How Recent Developments Are Shaping the Hikma Pharmaceuticals Story and Its Valuation
Hikma Pharmaceuticals’ consensus analyst price target has seen a slight dip, moving from £23.55 to £23.36 per share. This adjustment…
Read More » -
Is Regeneron Pharmaceuticals Stock Underperforming the S&P 500?
Tarrytown, New York-based Regeneron Pharmaceuticals, Inc. (REGN) discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases. Valued at $82.5 billion…
Read More » -
Is Vertex Pharmaceuticals Stock Underperforming the Nasdaq?
Vertex Pharmaceuticals Incorporated (VRTX), based in Boston, Massachusetts, is a prominent biotech firm specializing in the discovery, development, and commercialization of…
Read More » -
Sudeep Pharma shares rise nearly 29% over IPO price. What should investors do?
Sudeep Pharma extended its strong debut on Friday, rising close to 29% over its IPO price of Rs 593, signalling…
Read More » -
10 stocks to watch on Friday, Nov 28: Tata Power, Tata Elxsi, Emcure Pharma, GMR Airports, Wipro and more – Markets
10 stocks to watch on Friday, Nov 28 (Pic: Freepik/ ET NOW) Stocks To Watch Tomorrow, On Friday: Sensex and…
Read More » -
Is There an Opportunity in Ascendis Pharma After Regulatory Approval Fuels 52% Rally in 2025?
Thinking about Ascendis Pharma and wondering if it could be a hidden value play? You are not alone. Investors are…
Read More » -
Innocan Pharma Reports Financial Results for Q3 2025, with Revenues at US $21.6M
HERZLIYA, Israel and CALGARY, AB, Nov. 27, 2025 /PRNewswire/ — Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the “Company”…
Read More » -
Teva Pharmaceutical Industries (NYSE:TEVA): Evaluating Valuation After European Approval for Key Biosimilars
Teva Pharmaceutical Industries (NYSE:TEVA) has received European Commission approval for its biosimilars PONLIMSI and DEGEVMA. This development strengthens its position…
Read More »